ALZHEIMER’S DISEASE Alzheimer’s drugs are failing clinical trials, because we still do not understand what causes this complex disease.
44
Million People
worldwide have Alzheimer’s or a related dementia
In 2018, Alzheimer’s
cost the United States
$277 Billion
The cost of treating Alzheimer’s is expected to quadruple, to more than
$1 Trillion
in the U.S. by 2030, if no breakthrough treatments reach the market.
We haven’t had the tools we need to make real progress. Now, we do.
At NYSCF, we use the power of human patient stem
cells to study Alzheimer’s, which is bringing a paradigm shift to the entire field.
Alzheimer’s is a human disease, and we need human cells to really understand what causes it, develop more effective treatments, and find a cure. We have made patient stem cells from
9
DIFFERENT SUBTYPES
OF ALZHEIMER’S DISEASE,
making them available to scientists around the world and collaborating with
over
40 INSTITUTIONS
.